SELLAS Life Sciences Group (NASDAQ:SLS) Releases Quarterly Earnings Results, Meets Expectations

SELLAS Life Sciences Group (NASDAQ:SLS) announced its earnings results on Thursday. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05), FiscalAI reports.

SELLAS Life Sciences Group Trading Down 4.6%

Shares of SLS stock traded down $0.39 on Thursday, hitting $8.03. The company’s stock had a trading volume of 3,824,042 shares, compared to its average volume of 7,775,228. SELLAS Life Sciences Group has a fifty-two week low of $1.39 and a fifty-two week high of $15.88. The stock’s 50 day moving average is $11.27 and its 200-day moving average is $8.74.

Analysts Set New Price Targets

Several equities research analysts have issued reports on SLS shares. Alliance Global Partners restated a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $10.00.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.